Drugs / Brontictuzumab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03031691 | Jan → May 2017 | colorectal cancer | OncoMed Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01778439 | Feb 2013 → Jul 2016 | neoplastic disease or syndrome | OncoMed Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01703572 | Oct 2012 → Jan 2016 | lymphoma | OncoMed Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02662608 | Dec 2015 → Mar 2016 | adenoid cystic carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | brontictuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03031691 ↗ |
| Known as | OMP-52M51 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01703572 ↗ |
| Action | Inhibit | “NOTCH1 inhibitor brontictuzumab” NCT02662608 ↗ |
| Modality | Monoclonal antibody | — CHEMBL3545261 ↗ |
| Route | Intravenous | “1.5 mg/Kg intravenously every three weeks.” NCT02662608 ↗ |
| Target | NOTCH1 | “NOTCH1 inhibitor brontictuzumab” NCT02662608 ↗ |